Newsbenzinga
Milestone Pharmaceuticals Announces First European Patient Enrolled In Phase 3 Trial Of Etripamil For Atrial Fibrillation With Rapid Heart Rate
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…